Ribaxamase

Drug Profile

Ribaxamase

Alternative Names: Kymerase; P3A; SYN-004; Synthetic Bacillus licheniformis isoenzyme - Synthetic Biologics

Latest Information Update: 01 Jul 2017

Price : $50

At a glance

  • Originator Ipsat Therapies
  • Developer Synthetic Biologics
  • Class Aminohydrolases; Anti-infectives
  • Mechanism of Action Beta lactamase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Clostridium infections; Diarrhoea

Most Recent Events

  • 11 May 2017 Ribaxamase receives Breakthrough Therapy status for Clostridium infections (Prevention) in USA
  • 06 May 2017 Efficacy data from the phase IIb trials in Clostridium infections (Prevention) presented at the Digestive Disease Week 2017 (DDW-2017)
  • 02 Mar 2017 Synthetic Biologics plans to initiate phase III clinical trials for the prevention of C. difficile infections and antibiotic-associated diarrhoea, in the first half of 2018 or later
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top